Zacks Research Issues Optimistic Forecast for HALO Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Investment analysts at Zacks Research upped their FY2025 earnings per share (EPS) estimates for shares of Halozyme Therapeutics in a report issued on Tuesday, December 10th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of $4.45 per share for the year, up from their prior estimate of $4.40. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.80 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q3 2026 earnings at $1.44 EPS and FY2026 earnings at $5.84 EPS.

Several other brokerages have also recently issued reports on HALO. Wells Fargo & Company cut Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $58.00 to $62.00 in a research report on Monday, October 7th. Piper Sandler raised their target price on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $52.00 to $57.00 in a report on Thursday, September 19th. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Finally, JMP Securities lifted their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.11.

Halozyme Therapeutics Stock Up 0.4 %

HALO opened at $48.00 on Friday. The stock’s 50 day moving average price is $51.43 and its 200 day moving average price is $54.00. The stock has a market cap of $6.11 billion, a P/E ratio of 15.89, a P/E/G ratio of 0.43 and a beta of 1.23. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. Halozyme Therapeutics has a 12 month low of $33.15 and a 12 month high of $65.53.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of HALO. Congress Asset Management Co. raised its stake in Halozyme Therapeutics by 446.5% in the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after purchasing an additional 1,988,238 shares in the last quarter. Handelsbanken Fonder AB boosted its stake in shares of Halozyme Therapeutics by 76.9% in the 3rd quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after purchasing an additional 856,200 shares in the last quarter. Boston Trust Walden Corp acquired a new position in Halozyme Therapeutics during the 2nd quarter worth approximately $23,211,000. Dimensional Fund Advisors LP increased its holdings in shares of Halozyme Therapeutics by 12.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock worth $99,363,000 after buying an additional 209,530 shares in the last quarter. Finally, Federated Hermes Inc. boosted its holdings in shares of Halozyme Therapeutics by 37.8% during the 2nd quarter. Federated Hermes Inc. now owns 696,131 shares of the biopharmaceutical company’s stock valued at $36,449,000 after acquiring an additional 191,030 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Insider Activity

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $62.03, for a total transaction of $620,300.00. Following the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at $10,778,084.68. The trade was a 5.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 40,000 shares of company stock worth $2,242,100 in the last 90 days. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.